Table 4.

Reported adverse events during rituximab therapy for MN

ReferenceNRituximab Treatment DoseReported Adverse Events
Remuzzi et al. (2002), Ruggenenti et al. (2003)8375 mg/m2 once weekly × 4Generalized chills that spontaneously subsided (n = 1), skin rash that recovered after steroid pulse (n = 1), questionable laryngospasm that recovered after steroid pulse (n = 1)
Ratanatharathorn et al. (2003)1375 mg/m2 once weekly × 4None
Fra et al. (2003)1375 mg/m2 once weekly × 4None
Rossi et al. (2005)1375 mg/m2 once weekly × 4, then 375 mg/m2 once monthly × 5None
Rao (2005)2375 mg/m2 once weekly × 4Discontinued rituximab after two doses because of rash and wheezing during infusion (n = 1)
Srinivasan et al. (2005)2Not reportedNot reported
Jacobson et al. (2006)1375 mg/m2 once weekly × 4None
Cobo et al. (2006)1375 mg/m2 once weekly × 4None
Gallon and Chhabra (2006)1375 mg/m2 once weekly × 4None
Reddy et al. (2006)1Not reportedNot reported
Ruggenenti et al. (2006)23375 mg/m2 once weekly × 4Not reported
Terrier et al. (2007)1Not reportedSepticemia
Cravedi et al. (2007)12375 mg/m2 × 1 to 2 dosesNausea, chills, sweating, and face rush (n = 1)
Pansini et al. (2007)1375 mg/m2 once weekly × 4None
Fervenza et al. (2008)151 g × 2, on days 1 and 15; repeated at 6 mo if proteinuria >3 g/24h and CD19 + B cells >15/μlItching, rigors, and skin rash (n = 3); sore throat (n = 3); muscle pain (n = 1); serum sickness-like syndrome (n = 1); hair loss/thinning (n = 2); community acquired pneumonia (n = 1); fatigue and voice loss (n = 1); reactivated herpes zoster (n = 1); adenocarcinoma of lung with normal chest x-ray 1 yr before enrollment (n = 1)
Ferrannini et al. (2008)1375 mg/m2 once weekly × 4None
Troxell et al. (2008)4Not reportedNot reported
Weclawiak et al. (2008)1375 mg/m2 once weekly × 4, then 375 mg/m2 every 3 mo × 4None
Pixley et al. (2008)11 g × 2, on days 1 and 15; repeated at 6 moNot reported
Ruggenenti et al. (2008)7375 mg/m2 once weekly × 4Not reported